Boron and beyond: Where do we stand in cancer treatment?

Öz

Element boron(B) is in the IIIA group of the periodic table, with atom number 5 and a molecular weight of 10.81 mol/g. B is a rare element, and it involves many biological processes such as embryonic development, bone structure and function, oxidative stress, and, etc. Over the last decades, studies have shown that B-containing compounds regulate reactive oxygen species (ROS) levels, involve DNA damage mechanisms, and inhibit different enzymes. Improvements in medicine led researchers to think about B’s potential usage in cancer diagnosis, treatment, and prevention. Nowadays B-based compounds have been studied by different research groups on several types of cancer including prostate, lung, breast, colon, skin, brain, melanoma, etc. Studies revealed that B compounds can affect different types of cancers with different pathways/mechanisms. Based on the potential therapeutic effects of B, the first B-containing anticancer drug and a first-in-class proteasome inhibitor Bortezomib (Velcade®), was approved by the Food and Drug Administration (FDA) in 2003. On the other hand, boron neutron capture therapy (BNCT) is a very important clinical treatment for cancer which is based on B and B-containing delivery agents. During the past 20 years, researchers developed several new B delivery agents both for BNCT and B itself. In summary, this review article provides an overview of B compounds used for cancer diagnosis and treatment, delivery agents for BNCT, new therapeutic approaches containing B carriers, and novel B-based cancer detection approaches.

Anahtar Kelimeler

• Boron
• Cancer
• Anticancer Effects
• BNCT
• Phenylboronic Acid
• Boron Nitride
• Boron Delivery Agents

Bor ve ötesi: Kanser tanı ve tedavisinde neredeyiz?

Öz

Element boron(B) is in the IIIA group of the periodic table, with atom number 5 and a molecular weight of 10.81 mol/g. B is a rare element, and it involves many biological processes such as embryonic development, bone structure and function, oxidative stress, and, etc. Over the last decades, studies have shown that B-containing compounds regulate reactive oxygen species (ROS) levels, involve DNA damage mechanisms, and inhibit different enzymes. Improvements in medicine led researchers to think about B’s potential usage in cancer diagnosis, treatment, and prevention. Nowadays B-based compounds have been studied by different research groups on several types of cancer including prostate, lung, breast, colon, skin, brain, melanoma, etc. Studies revealed that B compounds can affect different types of cancers with different pathways/mechanisms. Based on the potential therapeutic effects of B, the first B-containing anticancer drug and a first-in-class proteasome inhibitor Bortezomib (Velcade®), was approved by the Food and Drug Administration (FDA) in 2003. On the other hand, boron neutron capture therapy (BNCT) is a very important clinical treatment for cancer which is based on B and B-containing delivery agents. During the past 20 years, researchers developed several new B delivery agents both for BNCT and B itself. In summary, this review article provides an overview of B compounds used for cancer diagnosis and treatment, delivery agents for BNCT, new therapeutic approaches containing B carriers, and novel B-based cancer detection approaches.

Anahtar Kelimeler

• Boron
• Kanser
• Anti-kanser Etki
• BNCT
• Fenilboronik asit
• Boron Nitrit
• Boron Taşıyıcı Ajanlar

Kaynakça

1. 1. Argust, P. (1998). Distribution of boron in the environment. Biological trace element research, 66(1), 131-143. https://doi.org/10.1007/BF02783133
2. 2. Karakaş, A. V., & Yilmaz, M. (2022). Türkiye’de Bulunan Bor Rezervlerinin Stratejik Açıdan Değerlendirilmesine Yönelik Akademik Algı. Ankara Üniversitesi Sosyal Bilimler Dergisi, 13(2), 10-25. http://dx.doi.org/10.33537/sobild.2022.13.2.2
3. 3. Etimine S.A. (2022) Boron Sector Report for 2021. Strategy Development Department.
4. 4. Białek, M., Czauderna, M., Krajewska, K. A., Przybylski, W. (2019). Selected physiological effects of boron compounds for animals and humans. A review. Journal of Animal and Feed Sciences, 28(4), 307-320. https://doi.org/10.22358/jafs/114546/2019
5. 5. Kar, Y., Şen, N., & Demirbaş, A. (2006). Boron minerals in Turkey, their application areas and importance for the country's economy. Minerals & Energy-Raw Materials Report, 20(3-4), 2-10 https://doi.org/10.1080/14041040500504293
6. 6. WHO.Boron.In: Trace elements in human nutrition and health. Geneva: World Health Organization;1996;p.175-9.
7. 7. Nielsen, F. H. (2017). Historical and recent aspects of boron in human and animal health .Journal of Boron , AGROBOR SPECIAL ISSUE , 153-160 . Retrieved from https://dergipark.org.tr/en/pub/boron/issue/33625/373093
8. 8. Gallardo‐Williams, M. T., Maronpot, R. R., Wine, R. N., Brunssen, S. H., & Chapin, R. E. (2003). Inhibition of the enzymatic activity of prostate‐specific antigen by boric acid and 3‐nitrophenyl boronic acid. The Prostate, 54(1), 44-49 https://doi.org/10.1002/pros.10166 .

9. 9. Devirian, T. A., & Volpe, S. L. (2003). Boron is probably important to human health–2003. Critical Reviews in Food Science and Nutrition, 43(2), 219-231.
10. 10. Baldwin, A. G., Tapia, V. S., Swanton, T., White, C. S., Beswick, J. A., Brough, D., & Freeman, S. (2018). Design, synthesis and evaluation of oxazaborine inhibitors of the NLRP3 inflammasome. ChemMedChem, 13(4), 312-320 https://doi.org/10.1002/cmdc.201700731
11. 11. Nocentini, A., Supuran, C. T., & Winum, J. Y. (2018). Benzoxaborole compounds for therapeutic uses: a patent review (2010-2018). Expert opinion on therapeutic patents, 28(6), 493-504 https://doi.org/10.1080/13543776.2018.1473379
12. 12. Baker, S. J., Zhang, Y. K., Akama, T., Lau, A., Zhou, H., Hernandez, V., ... & Plattner, J. J. (2006). Discovery of a new boron-containing antifungal agent, 5-fluoro-1, 3-dihydro-1-hydroxy-2, 1-benzoxaborole (AN2690), for the potential treatment of onychomycosis. Journal of medicinal chemistry, 49(15), 4447-4450 https://doi.org/10.1021/jm0603724
13. 13. Bradke, T. M., Hall, C., Carper, S. W., & Plopper, G. E. (2008). Phenylboronic acid selectively inhibits human prostate and breast cancer cell migration and decreases viability. Cell adhesion & migration, 2(3), 153-160 https://doi.org/10.4161/cam.2.3.6484
14. 14. McAuley, E. M., Bradke, T. A., & Plopper, G. E. (2011). Phenylboronic acid is a more potent inhibitor than boric acid of key signaling networks involved in cancer cell migration. Cell adhesion & migration, 5(5), 382-386 https://doi.org/10.4161/cam.5.5.18162
15. 15. Scorei, R., & Popa, R. (2010). Boron-containing compounds as preventive and chemotherapeutic agents for cancer. Anti-Cancer Agents in Medicinal Chemistry (Formerly current medicinal chemistry-Anti-Cancer agents), 10(4), 346-351 https://doi.org/10.2174/187152010791162289
16. 16. Nikkhah, S., & Naghii, M. R. (2017). Using boron supplementation in cancer prevention and treatment: a review article. The Cancer Press, 3, 113-119.
17. 17. Ciani, L., & Ristori, S. (2012). Boron as a platform for new drug design. Expert opinion on drug discovery, 7(11), 1017-1027 https://doi.org/10.1517/17460441.2012.717530
18. 18. Palumbo, A., Gay, F., Bringhen, S., Falcone, A., Pescosta, N., Callea, V., ... & Boccadoro, M. (2008). Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Annals of Oncology, 19(6), 1160-1165 https://doi.org/10.1093/annonc/mdn018
19. 19. Frankel, A., Man, S., Elliott, P., Adams, J., & Kerbel, R. S. (2000). Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clinical Cancer Research, 6(9), 3719-3728.
20. 20. Fernandes, G. F. S., Denny, W. A., & Dos Santos, J. L. (2019). Boron in drug design: Recent advances in the development of new therapeutic agents. European Journal of Medicinal Chemistry, 179, 791-804 https://doi.org/10.1016/j.ejmech.2019.06.092
21. 21. Offidani, M., Corvatta, L., Caraffa, P., Gentili, S., Maracci, L., & Leoni, P. (2014). An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma. OncoTargets and therapy, 1793-1800 https://doi.org/10.2147/OTT.S49187
22. 22. Food and Drug Administration. (2017). Novel drug approvals for 2017. 2020-12-20]. https://www. fda. gov/drugs/new-drugs-fda-cders-new-molecular-entities-andnewtherapeutic-biological-products/novel-drug approvals-2019US.
23. 23. Cui, Y., Winton, M. I., Zhang, Z. F., Rainey, C., Marshall, J., De Kernion, J. B., & Eckhert, C. D. (2004). Dietary boron intake and prostate cancer risk. Oncology reports, 11(4), 887-892 https://doi.org/10.3892/or.11.4.887
24. 24. Korkmaz, M., Uzgören, E., Bakırdere, S., Aydın, F., & Ataman, O. Y. (2007). Effects of dietary boron on cervical cytopathology and on micronucleus frequency in exfoliated buccal cells. Environmental Toxicology: An International Journal, 22(1), 17-25 https://doi.org/10.1002/tox.20229
25. 25. Mahabir, S., Spitz, M. R., Barrera, S. L., Dong, Y. Q., Eastham, C., & Forman, M. R. (2008). Dietary boron and hormone replacement therapy as risk factors for lung cancer in women. American journal of epidemiology, 167(9), 1070-1080 https://doi.org/10.1093/aje/kwn021
26. 26. Scorei, R. I., & Popa, R. (2013). Sugar-borate esters–potential chemical agents in prostate cancer chemoprevention. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 13(6), 901-909.
27. 27. Hunter, J. M., Nemzer, B. V., Rangavajla, N., Biţă, A., Rogoveanu, O. C., Neamţu, J., ... & Mogoşanu, G. D. (2019). The fructoborates: part of a family of naturally occurring sugar–borate complexes—biochemistry, physiology, and impact on human health: a review. Biological trace element research, 188(1), 11-25 https://doi.org/10.1007/s12011-018-1550-4
28. 28. Petasis, N. A. (2007). Expanding roles for organoboron compounds–Versatile and valuable molecules for synthetic, biological and medicinal chemistry. Australian Journal of Chemistry, 60(11), 795-798.
29. 29. Arai, M., Koizumi, Y., Sato, H., Kawabe, T., Suganuma, M., Kobayashi, H., ... & Omura, S. A. T. O. S. H. I. (2004). Boromycin abrogates bleomycin-induced G2 checkpoint. The Journal of antibiotics, 57(10), 662-668 https://doi.org/10.7164/antibiotics.57.662
30. 30. Soriano-Ursúa, M. A., Das, B. C., & Trujillo-Ferrara, J. G. (2014). Boron-containing compounds: chemico-biological properties and expanding medicinal potential in prevention, diagnosis and therapy. Expert Opinion on Therapeutic Patents, 24(5), 485-500 https://doi.org/10.1517/13543776.2014.881472